UAE doctor who went viral for brave stance during Covid returns after 20 years
An Emirati oncologist who went viral in 2020 for deciding to stay in the US to treat Covid patients and not leave has returned to his homeland after 20 years of living abroad. And he has two key missions: Reduce the cost of one of the most expensive cancer treatments and remove misconceptions around the scary 'C word. '
The first thing Dr Ajlan Al Zaki noticed in his patients here in the UAE was an instilled fear of cancer. 'It's okay to say the C word. A lot of patients come in and they hear the word cancer and that brings in fear. There are concerns, and understandably so. They just want to make sure that they're okay. That sort of awareness needs to be spread out where cancer is not necessarily a bad word,' he told Khaleej Times.
Another thing he noticed in patients here was how everything was taken at face value. 'We tend to use Dr Google or AI,' Al Zaki said. 'I need to tell my patients don't believe everything you read online. Please don't do it. You can Google a little bit, but don't believe everything you read online.'
Dr Al Zaki, a triple board-certified haematologist and oncologist previously based out of the US, went viral during the beginning of the Covid pandemic in 2020 after the UAE government called on its citizens abroad to return home, but he decided not to leave and to stay in order to perform his duty as a doctor and treat infected patients.
Currently, he is director of Burjeel Haematology Oncology and Cellular Therapy Centre and a specialist in CAR-T cell and Advanced immunotherapies. 'The UAE has supported me during this whole time. I was going through my personal journey of developing experience and getting that experience where I felt like I would be comfortable enough to bring everything back,' Al Zaki said.
More affordable CAR-T cell therapy
Today, the haematologist-oncologist is continuing his path of helping cancer patients by reducing the costs of one of the most personalised and expensive cancer treatments–chimeric antigen receptor CAR-T cell therapy. This type of treatment involves genetically engineering a patient's T-cells and training them to recognise a specific marker on a cancer cell and then fighting those off once given back to the patient. Because this treatment is so personalised, the costs of treatment are significantly higher. One single infusion could cost a whopping $1 million.
During the first day of the Abu Dhabi Global Health Week event, which ran from April15-17, Burjeel Holdings announced its partnership with Caring Cross, a US-based non-profit, to reduce the costs of CAR T cell therapy treatment by up to 90% compared to international costs. 'It could be up to 90%, where that bar is going to be in the UAE, we don't know. But I know for sure that we can provide it at a lower cost than what's commercially approved,' Al Zaki said.
Al Zaki explained that the reason why costs may be reduced by that much is due to the technology offered by Caring Cross to locally manufacture the cells. 'When you're making the CAR-T cells, when you're programming the CAR-T cells, think of it as downloading software on your iPhone. So, you have your iPhone, which is your T cells, and you want to upgrade your iPhone, you have to download software,' he said.
Al Zaki continued: 'It's the software sometimes which can be really expensive. And so, what Caring Cross does is they make the software, and they provide it at a significantly reduced cost. And we use that software to then upgrade the T cells.'
'I want people to have access to these kinds of therapies anywhere in the world. That's why we went into medicine,' he said.
From engineering to medicine
After starting his academic journey as a chemical engineer, Al Zaki came across a professor who suggested that he tries to do some research. At the time, Al Zaki had plans to work for one of the oil companies in the UAE. However, that eye-opening conversation prompted him to switch course and turn to research as a career path. 'The idea of cancer always intrigued me at that time. How do we diagnose it? How do we treat it? What are new ways that we are using to prevent it from occurring in the beginning?' he said.
Six years and a PhD in research later, Al Zaki decided that medicine was his true calling and pursued medical school.
In 2012, when his grandfather was diagnosed with late-stage cancer, Al Zaki grew inspired to help people when they are at their worst, whether it be medical or emotional support. He said that despite the condition his grandfather was in, he knew how important it was to just be present. 'I read once that sometimes the best therapy that you can give to a patient that's not administered by way of mouth or way of the vein, is really through the way of the ear. Sometimes [words of comfort are] the strongest therapy you can give to someone.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
2 days ago
- Arabian Post
AI‑Powered Phage Therapy Set to Tackle Antibiotic Resistance
Phagos, a Paris‑based biotech startup, is deploying an artificial‑intelligence model built on Amazon Web Services to accurately match bacteriophages with antibiotic‑resistant bacterial strains. This development marks a pivotal shift from arbitrary trial‑and‑error methods to precision medicine in combating infections that claim an estimated one million lives annually. The challenge of antibiotic resistance has spurred Phagos, co‑founded by microbiologist Adèle James and economist Alexandros Pantalis, to pursue alternative therapies. Phages are viruses that specifically infect bacteria, a property that enables targeted treatment without disrupting beneficial microorganisms. But identifying the right phage for a given pathogen has traditionally required labour‑intensive screening of millions of combinations. Phagos is leveraging AWS's Generative AI Accelerator Programme, which has provided them with cloud credits, embedded AWS architects and machine‑learning engineers, and dedicated mentorship, to build a generative AI platform capable of predicting effective pairings between phages and bacterial strains. The AI model has been trained on datasets from public repositories and proprietary lab results. ADVERTISEMENT 'We can now read into the DNA and see if there's going to be an interaction between a phage and a bacterium,' Pantalis explained. This capability bypasses exhaustive wet‑lab testing and accelerates the discovery pipeline. Phagos's strategy involves initial trials in animal health—shrimp, chicken, bovine, swine—with phages administered through water systems to curb infections in farm environments. James noted that reducing antibiotic use in livestock is critical, as drug‑resistant bacteria generated in farms can transfer to humans via environmental pathways. The startup's first validation came from a collaboration with an oyster farmer in France, where AI‑matched phages slashed mortality by 40 per cent. Technical infrastructure from AWS played a crucial role, with cloud experts helping to refine the system and scale it efficiently. 'We became much faster, and spent way less time figuring out how to set up our infrastructure,' James said. Globally, the antibiotic resistance crisis is projected to cause more deaths than cancer by mid‑century, with economic impacts exceeding US$1.5 trillion. By automating phage matching, Phagos aims to create personalised and adaptive therapies that evolve in tandem with bacterial mutations. Participation in AWS's 2024 accelerator—which selected just 80 startups from over 4,700 applicants—has provided Phagos not only with technical and financial support, but also exposure to industry networks and potential funding sources. The platform-as‑a‑service model being developed by Phagos positions the company as a pioneer in AI‑driven microbiological model building. One quarter of its team now focuses exclusively on data and machine learning, a rarity in biotech. Expansion plans are underway: the company intends to move into human therapeutic applications by 2030, while continuing its work in agriculture. It is also advancing bespoke phage therapies, distinguishing itself from generic phage cocktails pursued by competitors. While obstacles remain—such as regulatory pathways for phage-based treatments and the complexity of bacterial ecosystems—Phagos believes its AI model and cloud infrastructure provide a scalable solution. Each new phage cocktail generates data that feeds into the platform, enhancing future predictions.
Dubai Eye
2 days ago
- Dubai Eye
Death toll rises in Gaza as aid-seeking crowds come under fire
Dozens of Palestinians have been killed by Israeli fire in the past two days while trying to access food aid in Gaza, amid a worsening hunger crisis, according to local medics. On Thursday, medics reported at least 51 people killed by Israeli gunfire and airstrikes. Among them were 12 Palestinians who tried to approach a site operated by the US-backed Gaza Humanitarian Foundation (GHF) in the central part of the Strip. The incident is the latest in a string of deadly encounters involving civilians seeking food. The Israeli military said several individuals it described as "suspects" approached its forces near the Netzarim corridor in central Gaza in a way that endangered troops. It said soldiers fired warning shots to deter them and that it was not aware of any injuries at the time. Elsewhere in Gaza on Thursday, medics reported 39 people killed in separate Israeli airstrikes in the north of the territory. One strike on the Shati refugee camp in Gaza City killed at least 19 people, including women and children. Another strike killed at least 14 people in Jabalia and damaged several homes. There was no immediate comment from the Israeli army on those attacks. Gaza's health ministry said hundreds of Palestinians have been killed while trying to reach GHF distribution sites since late May. The United Nations has criticized the GHF's delivery system, calling it inadequate, dangerous and a violation of humanitarian impartiality. Israel defends the system as a necessary safeguard against diversion of aid by Hamas, a claim Hamas denies. GHF said Wednesday it had distributed 3 million meals across three sites in Gaza without incident. The war in Gaza began after Hamas launched a surprise attack on Israel on October 7, 2023, killing 1,200 people and taking 251 hostages, according to Israeli figures. Israel's ongoing military campaign has since killed nearly 55,600 Palestinians, according to Gaza's health ministry, displaced nearly the entire population of over 2 million, and left much of the territory in humanitarian collapse.
Web Release
3 days ago
- Web Release
Burjeel Holdings' JV Alkalma Launches Regional Mental Health Platform with Four Premier Centers in the UAE and Saudi Arabia
In a strategic move to enhance access to mental health services across the region, Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has launched four specialist mental health centers under its mental health and wellbeing platform, Alkalma, through the integration of Aspris Healthcare facilities. The centers, located in Dubai's City Walk and Dubai Healthcare City, Abu Dhabi's Al Bateen, and Riyadh's King Abdullah Financial District, are recognized for delivering personalized, adaptable mental healthcare across a wide spectrum of psychological needs. These newly integrated centers deliver personalized care through a range of therapy formats, including individual, group, and family sessions, now aligned with Alkalma's mission to build a value-driven mental healthcare ecosystem rooted in prevention, accessibility, and overall wellbeing. Together, the four centers offer a combined annual capacity of approximately 90,000 consultations. Although mental health conditions affect up to one in five individuals annually, they account for less than 5% of total health spending across the region. This underinvestment is compounded by a persistent shortage of clinical professionals and limited access to integrated networks, highlighting a critical gap that Alkalma is designed to address. This launch marks the first phase of a multi-year expansion strategy. By establishing a presence in major urban markets and aligning operations with Keralty's globally validated, value-based care models, Alkalma is laying the foundation for a scalable platform positioned to meet rising demand and deliver measurable health and economic outcomes. John Sunil, Chief Executive Officer of Burjeel Holdings, said: 'Integrating these centers into our ecosystem marks a pivotal step in realizing our vision for a regional mental health platform rooted in Alkalma's values of clinical excellence and inclusivity. It enables us to expand access to high-quality care while accelerating the delivery of outcomes that matter to patients and health systems alike.' Alkalma was launched as a strategic joint venture between Burjeel Holdings and Colombia-based healthcare leader Keralty, a global organization with nearly five decades of experience in value-based care. As a founding partner, Keralty brings deep expertise in delivering integrated mental health and primary care services across nine countries, including the U.S., supporting over 500,000 individuals globally in behavioral health. Dr. Emilio Herrera, CEO of Alkalma, said: 'At Alkalma, we believe a healthcare system is defined by how it supports those most in need. There is no health without mental health. Establishing our presence in the UAE and Saudi Arabia reflects our commitment to advancing national priorities and bringing the best scientific evidence, the highest quality of care, to serve the community. This is only the beginning.' Shorooq, a leading regional investment manager, facilitated the strategic integration of Aspris Healthcare facilities. Mahmoud Adi, Founding Partner at Shorooq, said: 'We are proud to see these facilities become foundational to a regionally integrated mental health ecosystem. We believe private equity can be a transformative force in sectors that touch people's lives.' In the coming months, Alkalma will fully integrate these centers under a unified brand, expand clinical capacity, and launch a digital mental-health platform to reach under-served populations. Further centers in new communities across the UAE and Saudi Arabia are under review as part of the JV's regional scale-up plan. Alkalma is positioned to play a defining role in shaping the region's next-generation mental health ecosystem, delivering value across patients, systems and stakeholders.
